Latest news with #DanielBrennan
Yahoo
11-08-2025
- Business
- Yahoo
TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN)
Myriad Genetics, Inc. (NASDAQ:MYGN) is one of the . On August 5, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics, Inc. (NASDAQ:MYGN) with a $6 price target. The rating follows the company's fiscal second quarter 2025 earnings release, where the company posted a strong quarter after a weaker first quarter for 2025. Myriad Genetics, Inc. (NASDAQ:MYGN) posted revenue of $213.10 million, reflecting around 1% year-over-year growth and ahead of expectations by $10.8 million. The EPS of $0.05 also exceeded expectations by $0.06. A medical professional in a laboratory analyzing the outcomes of a molecular diagnostic test. Brennan noted that this was mainly due to a solid performance in Hereditary Cancer Testing and GeneSight. However, he highlighted that the Prenatal segment remains weak, and the outlook for the second half of 2025 hints at a possible decline in year-over-year growth. The company also faces challenges from the loss of a GeneSight contract and issues with electronic medical records affecting volumes, thereby resulting in a cautious rating from the analyst. Myriad Genetics, Inc. (NASDAQ:MYGN) is a genetic testing and precision medicine company that develops genetic tests to help assess disease risk and guide treatment decisions. While we acknowledge the potential of MYGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Time of India
02-07-2025
- Business
- Time of India
Atharva gets achievers award at London
CEO of Drishti Pures and director of Drishti Samajik Sansthan, Atharva Bahadur was honoured with the Cluster of Achievers Award (COA) at the Palace of Westminster, House of Lords, London. Tired of too many ads? go ad free now He received the title of best sustainable entrepreneur supporting specially abled for his exceptional work in training around 20 abandoned, multiple challenged grown-ups at Drishti Pures, a unit producing pure mustard oil and processing over 30 varieties of spices. The award was presented by Lord Daniel Brennan, Member of the British Parliament, and councillor Sunil Chopra from the House of Lords council department. Atharva also participated in a panel discussion on creating a better educational environment at the University of Oxford.
Business Insider
14-05-2025
- Business
- Business Insider
Seer (SEER) Gets a Buy from TD Cowen
TD Cowen analyst Daniel Brennan reiterated a Buy rating on Seer (SEER – Research Report) today. The company's shares closed today at $1.92. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Brennan covers the Healthcare sector, focusing on stocks such as Illumina, NeoGenomics, and Exact Sciences. According to TipRanks, Brennan has an average return of 7.5% and a 41.23% success rate on recommended stocks. Seer has an analyst consensus of Moderate Buy, with a price target consensus of $3.00. Based on Seer's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.95 million and a GAAP net loss of $21.74 million. In comparison, last year the company earned a revenue of $4.18 million and had a GAAP net loss of $17.8 million
Yahoo
24-04-2025
- Business
- Yahoo
BSX Q1 Earnings Call: Outperformance Driven by Cardiology and Electrophysiology, Guidance Raised Amid Tariff Headwinds
Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion. The company expects next quarter's revenue to be around $4.88 billion, close to analysts' estimates. Its non-GAAP profit of $0.75 per share was 11.5% above analysts' consensus estimates. Is now the time to buy BSX? Find out in our full research report (it's free). Revenue: $4.66 billion vs analyst estimates of $4.57 billion (20.9% year-on-year growth, 2% beat) Adjusted EPS: $0.75 vs analyst estimates of $0.67 (11.5% beat) Adjusted EBITDA: $1.45 billion vs analyst estimates of $1.31 billion (31.2% margin, 11.3% beat) Revenue Guidance for Q2 CY2025 is $4.88 billion at the midpoint, roughly in line with what analysts were expecting Management raised its full-year Adjusted EPS guidance to $2.91 at the midpoint, a 2.5% increase Operating Margin: 19.8%, up from 17.5% in the same quarter last year Free Cash Flow was $511.4 million, up from -$15 million in the same quarter last year Organic Revenue rose 18.2% year on year (13.1% in the same quarter last year) Market Capitalization: $146.3 billion Boston Scientific's first quarter results were shaped by broad-based momentum in its cardiology and electrophysiology businesses. Management highlighted that double-digit growth in five of eight business units and strong adoption of key platforms like FARAPULSE and WATCHMAN contributed to the company's outperformance. CEO Mike Mahoney emphasized, 'Our strong growth continues to reflect the durability of our category leadership strategy, which is powered through meaningful innovation and clinical evidence generation.' Looking forward, management's raised full-year guidance incorporates both continued portfolio strength and the anticipated impact of new tariffs. CFO Daniel Brennan noted that while tariffs present a $200 million headwind, the company expects to offset these through increased sales and discretionary spending reductions. Mahoney added, 'We remain excited about our near and long-term growth catalysts, which we believe will enable us to deliver consistent differentiated performance this year and well beyond.' Management attributed the quarter's outperformance to execution across core businesses, successful integration of recent acquisitions, and ongoing investment in clinical and manufacturing capabilities. Cardiology and Electrophysiology Surge: Cardiology sales grew substantially, with management pointing to strong demand for FARAPULSE (a pulsed field ablation system used in cardiac arrhythmia treatment) and the WATCHMAN left atrial appendage closure device. These platforms benefited from increased adoption, new account openings, and supporting clinical data. Geographic Expansion: The U.S. market experienced over 30% operational growth, while Japan and China also contributed meaningfully. Management noted that China, despite pricing pressures from volume-based procurement (VBP), is expected to maintain double-digit growth due to local partnerships and product launches. Integration of Acquisitions: The company completed the acquisitions of Bolt Medical and made progress integrating Axonics and other recently acquired businesses. These moves expand Boston Scientific's footprint in interventional cardiology, peripheral interventions, and urology. Pipeline Progress and Regulatory Milestones: Management highlighted ongoing clinical trials and anticipated regulatory approvals for next-generation products—including the Empower leadless pacemaker, expanded indications for WATCHMAN, and new mapping solutions for electrophysiology. Tariff and Supply Chain Management: The team acknowledged that new tariffs will impact costs in the second half of the year but stated they will not shift manufacturing locations, instead focusing on managing discretionary spending to protect margins. Management's outlook for the next quarter and the full year is underpinned by continued demand in core therapeutic categories, the expected contributions from recent product launches, and disciplined cost management in the face of new tariffs. Core Portfolio Momentum: Management expects sustained demand for FARAPULSE, WATCHMAN, and emerging electrophysiology products to drive above-market growth in key geographies. Mitigating Tariff Headwinds: The company plans to counteract a $200 million tariff impact primarily through higher sales, selective cost controls, and minor foreign exchange benefits, rather than changes to the manufacturing footprint. Ongoing Pipeline and Integration: New clinical data readouts, regulatory milestones, and the integration of new acquisitions such as SoniVie and Entera Oncology are expected to contribute to both revenue growth and portfolio diversification. Robert Marcus (JPMorgan): Asked about the ability to offset $200 million in tariffs and whether manufacturing would shift. Management replied that increased sales and spending reductions would cover the headwind, with no plans to change manufacturing locations. Larry Biegelsen (Wells Fargo): Questioned Boston Scientific's goal to become the #1 player in electrophysiology. CEO Mike Mahoney said this is the company's aim, driven by clinical leadership and geographic expansion, especially in China and Japan. Joanne Wuensch (Citi): Requested details on WATCHMAN's growth and uptake of combined procedures. Management cited faster-than-expected adoption and highlighted benefits for patients, physicians, and hospitals. Frederick Wise (Stifel): Asked about the broader impact of trade tensions and supply chain risks in China. Mahoney stated that double-digit growth is expected in China despite VBP pressures, supported by local manufacturing and partnerships. David Roman (Goldman Sachs): Inquired about drivers for moving MedSurg growth from mid-single to high-single digits. Management pointed to integration of acquisitions, improvements in neuromodulation, and some ongoing supply chain challenges in urology. In the coming quarters, the StockStory team will focus on (1) the uptake and broader clinical adoption of FARAPULSE and next-generation electrophysiology platforms, (2) progress on regulatory approvals and expanded indications for products like WATCHMAN and Empower, and (3) evidence of successful integration and revenue contributions from recent acquisitions such as SoniVie and Bolt Medical. We will also monitor the company's ability to offset tariff headwinds while sustaining margin expansion. Is BSX a buy or sell post earnings? The answer lies in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Business Journals
24-04-2025
- Business
- Business Journals
Petri Dish: Boston Scientific CFO retires, Seres' reverse stock split
Over the last week, Boston Scientific announced a forthcoming CFO change, Seres' reverse stock split and a Flagship startup's new pharma partnership. Story Highlights Repertoire Immune Medicines partners with Genentech for autoimmune disease treatments. Boston Scientific CFO Daniel Brennan to retire after 30 years. Seres Therapeutics implements 1-for-20 reverse stock split to boost share price. In recent days, Boston Scientific announced a forthcoming CFO change, a Cambridge biotech undertook a 1-for-20 reverse stock split and a Flagship startup announced an expanded partnership with Genentech. Repertoire expands Genentech deal The Flagship spinout Repertoire Immune Medicines has signed another deal with a big pharma partner. The Cambridge startup will work with Genentech, the California-based subsidiary of Roche, to discover and develop T cell-targeted immune medicines to treat an autoimmune disease. The collaboration and license agreement will earn Repertoire $35 million upfront as well as potentially up to $730 million in additional development, regulatory and commercial milestones, as well as tiered royalties. Almost exactly one year ago, Repertoire announced a multi-year collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The deal was worth $65 million upfront and up to $1.8 billion for hitting certain milestones. Boston Scientific CFO to retire Boston Scientific Corp. (NYSE: BSX) announced that CFO Daniel Brennan will retire from his role after nearly 30 years with the company. Brennan's last day will be at the end of June, but he will stay on as a senior advisor through early October 2025. Stepping into the role of chief financial officer is Jonathan Monson, who is currently Boston Scientific's senior vice president of investor relations. Seres' reverse stock split Seres Therapeutics Inc. went through with a 1-for-20 reverse stock split, a move typically undertaken by a company to increase its share price. The Cambridge biotech's common stock began trading on a split-adjusted basis on Tuesday. Seres' (Nasdaq: MCRB) shares were priced at almost $10 apiece on Wednesday afternoon and its market cap was $86.83 million. Last year, Seres sold full ownership of its microbiome pill, Vowst, to Nestlé Health Science. Vowst was approved in 2023 after about a decade of development. Seres said more than one-third of its employees would transfer to Nestlé. Subscribe to our BioFlash, TechFlash and Real Estate newsletters — all free.
